

Accepted Manuscript

Critical differences in drug metabolic properties of human hepatic cellular models, including primary human hepatocytes, stem cell derived hepatocytes, and hepatoma cell lines

Alexander J. Kvist, Kajsa P. Kanebratt, Anna Walentinsson, Henrik Palmgren, Matthew O'Hara, Anders Björkbom, Linda C. Andersson, Marie Ahlqvist, Tommy B. Andersson

PII: S0006-2952(18)30239-9
DOI: <https://doi.org/10.1016/j.bcp.2018.06.026>
Reference: BCP 13180

To appear in: *Biochemical Pharmacology*

Received Date: 27 April 2018
Accepted Date: 21 June 2018

Please cite this article as: A.J. Kvist, K.P. Kanebratt, A. Walentinsson, H. Palmgren, M. O'Hara, A. Björkbom, L.C. Andersson, M. Ahlqvist, T.B. Andersson, Critical differences in drug metabolic properties of human hepatic cellular models, including primary human hepatocytes, stem cell derived hepatocytes, and hepatoma cell lines, *Biochemical Pharmacology* (2018), doi: <https://doi.org/10.1016/j.bcp.2018.06.026>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Critical differences in drug metabolic properties of human hepatic cellular models, including primary human hepatocytes, stem cell derived hepatocytes, and hepatoma cell lines.

Alexander J. Kvist^{1**}, Kajsa P. Kanebratt^{2*}, Anna Walentinsson³, Henrik Palmgren⁴, Matthew O'Hara⁵, Anders Björkbom², Linda C. Andersson⁶, Marie Ahlqvist², and Tommy B. Andersson^{2,7}

1. IMED Operations Project Management, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
2. Drug Metabolism and Pharmacokinetics, Cardiovascular and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Sweden
3. Translational Sciences, Cardiovascular and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Sweden
4. Bioscience Diabetes, Cardiovascular and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Sweden
5. University Health Network, Toronto, Ontario, Canada
6. Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca Gothenburg, Sweden
7. Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden

* Authors contributed equally

Corresponding author

Download English Version:

<https://daneshyari.com/en/article/8523796>

Download Persian Version:

<https://daneshyari.com/article/8523796>

[Daneshyari.com](https://daneshyari.com)